|Mr. Paul J. Hastings||Chairman, Chief Exec. Officer and Pres||799.94k||N/A||57|
|Dr. John A. Lewicki Ph.D.||Exec. VP of R&D||554.27k||N/A||65|
|Mr. Sunil Patel||Chief Financial Officer and Sr. VP of Corp. Devel. & Fin.||N/A||N/A||45|
|Michelle Corral||Sr. Director of Investor Relations and Corp. Communications||N/A||N/A||N/A|
|Dr. Alicia J. Hager J.D., Ph.D.||Sr. VP and Gen. Counsel||N/A||N/A||47|
OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The companys product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand. The company has strategic alliances with GlaxoSmithKline LLC to develop and commercialize antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.
OncoMed Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 7.